Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)

NCT03358875 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

805

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Tislelizumab
DRUG: Docetaxel

Sponsor

BeiGene